Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov;144(5):672-681.
doi: 10.4103/ijmr.IJMR_650_15.

Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report

Sarayu A Pai  1 , Nilima A Kshirsagar  1
Affiliations

Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report

Sarayu A Pai et al. Indian J Med Res. 2016 Nov.

Abstract

Background & objectives: With pioglitazone ban and subsequent revoking in India along with varying regulatory decisions in other countries, it was decided to carry out a systematic review on its safety, efficacy and drug utilization in patients with type 2 diabetes mellitus (T2DM) in India and compare with the data from the European Medicines Agency Assessment Report (EMA-AR).

Methods: Systematic review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching Medline/PubMed, Google Scholar and Science Direct databases using 'pioglitazone AND India AND human' and 'pioglitazone AND India AND human AND patient' and compared with EMA-AR. Spontaneous reports in World Health Organization VigiBase from India were compared with VigiBase data from other countries.

Results: Sixty six publications, 26 (efficacy), 32 (drug utilization) and eight (safety), were retrieved. In India, pioglitazone was used at 15-30 mg/day mostly with metformin and sulphonylurea, being prescribed to 26.7 and 8.4 per cent patients in north and south, respectively. The efficacy in clinical trials (CTs) was similar to those in EMA-AR. Incidence of bladder cancer in pioglitazone exposed and non-exposed patients was not significantly different in an Indian retrospective cohort study. There were two cases and a series of eight cases of bladder cancer published but none reported in VigiBase.

Interpretation & conclusions: In India, probably due to lower dose, lower background incidence of bladder cancer and smaller sample size in epidemiological studies, association of bladder cancer with pioglitazone was not found to be significant. Reporting of CTs and adverse drug reactions to Clinical Trials Registry of India and Pharmacovigilance Programme of India, respectively, along with compliance studies with warning given in package insert and epidemiological studies with larger sample size are needed.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Figures

Figure
Figure
Flowchart showing selection of articles for inclusion in systematic review (SR).
See this image and copyright information in PMC

References

    1. French regulators suspend pioglitazone citing cancer risk. [accessed on August 24, 2015]. Available from: http://www.medscape.com/viewarticle/744345 .
    1. FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer. [accessed on August 24, 2015]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm .
    1. Jadhav SS, Shivane VK, Lila AR, Bandgar TR, Shah NS. Pioglitazone: hype and hope. J Postgrad Med. 2014;60:293–6. - PubMed
    1. Agency EM. Assessment Report for Actos, Glustin, Competact, Glubrava, Tandemact. [accessed on November 10, 2014]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_R... .
    1. Moher D, Liberati A, Tetzlaff J, Altman DG PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9, W64. - PubMed

Publication types

MeSH terms